• Cangene Corp., of Winnipeg, Manitoba, granted Camurus AB, of Lund, Sweden, exclusive U.S. commercialization rights for episil in managing pain associated with oral lesions, including oral mucositis, resulting from cancer therapy and other causes. Financial terms were not disclosed.